Super League Enterprise raises $1.21M via convertible preferred stock with $1.25 conversion price

Super League Enterprise, Inc.

Raised $1.21M in gross proceeds from sale of 1,210 shares of Series AAA convertible preferred stock at $1,000/share.
Initial conversion price set at $1.25 per common share, subject to future adjustments for equity issuances.
Dividends: holders receive shares equal to 20% of underlying common at 30/60/90 day anniversaries; also participates in common dividends.
Additional investment right for 18 months: purchasers can buy more shares at $1,000 with $1.25 conversion, subject to stockholder approval.
Placement agent received $121K cash fee, $24.2K expense allowance, and warrants for 140,360 shares at $1.25.

item 1.01 item 3.02 item 5.03 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-24-022016
form_type: 8-K
ticker: SLE
cik: 0001621672
company_name: Super League Enterprise, Inc.
filed_at: 2024-07-02T23:59:59+00:00
discovered_at: 2026-05-14T18:03:13.835748+00:00
generated_at: 2026-05-31T23:46:58.598163+00:00
sec_items: ["1.01", "3.02", "5.03", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-24-022016
json_url: https://secwatch.observer/filing/0001437749-24-022016.json
markdown_url: https://secwatch.observer/filing/0001437749-24-022016.md
text_url: https://secwatch.observer/filing/0001437749-24-022016.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1621672/000143774924022016/0001437749-24-022016-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1621672/000143774924022016/slgg20240701_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 1.01, 3.02, 5.03, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ZSPC

zSpace restructures $12M debt via equity conversion; creates Series P-2 preferred

zSpace, Inc. June 1, 2026, 8:00 AM ET other_material Items 1.01, 1.02, 2.03, 3.02, 5.03, 9.01

same SEC item: 1.01, 3.02, 5.03, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

Filing page SEC filing

STSS

Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South

Sharps Technology Inc. June 1, 2026, 8:15 AM ET other_material Items 5.03, 8.01, 9.01

same SEC item: 5.03, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

LBTYA

Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027

Liberty Global Ltd. June 1, 2026, 4:07 PM ET other_material Items 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001437749-24-022016

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.